Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ATHX | Athersys Inc

Index	-	P/E	-	EPS (ttm)	-3.03	Insider Own	2.71%	Shs Outstand	22.50M	Perf Week	31.81%
Market Cap	9.85M	Forward P/E	-	EPS next Y	-0.75	Insider Trans	0.00%	Shs Float	21.89M	Perf Month	-6.89%
Income	-47.41M	PEG	-	EPS next Q	-0.21	Inst Own	19.35%	Short Float / Ratio	3.62% / 1.92	Perf Quarter	-52.41%
Sales	0.15M	P/S	65.64	EPS this Y	82.70%	Inst Trans	20.68%	Short Interest	0.79M	Perf Half Y	-57.92%
Book/sh	-1.71	P/B	-	EPS next Y	28.57%	ROA	-207.55%	Target Price	5.50	Perf Year	-76.35%
Cash/sh	0.08	P/C	5.47	EPS next 5Y	-	ROE	-1276.02%	52W Range	0.26 - 2.76	Perf YTD	-47.90%
Dividend	-	P/FCF	-	EPS past 5Y	-84.03%	ROI	-	52W High	-84.14%	Beta	-0.75
Dividend %	-	Quick Ratio	0.09	Sales past 5Y	136.67%	Gross Margin	-2.74%	52W Low	70.94%	ATR	0.06
Employees	24	Current Ratio	0.09	Sales Q/Q	-97.88%	Oper. Margin	-34380.14%	RSI (14)	55.68	Volatility	14.17% 15.33%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	72.58%	Profit Margin	-32469.18%	Rel Volume	0.89	Prev Close	0.42
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 16 AMC	Payout	-	Avg Volume	412.73K	Price	0.44
Recom	1.00	SMA20	16.23%	SMA50	-5.49%	SMA200	-53.58%	Volume	368,521	Change	3.94%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-19-21	Downgrade	BofA Securities	Buy → Neutral
Jun-25-20	Initiated	BofA/Merrill	Buy	$5
Aug-26-19	Initiated	Dawson James	Buy	$11
Feb-13-18	Reiterated	Maxim Group	Buy	$12 → $6
Aug-10-17	Reiterated	Maxim Group	Buy	$9 → $12
Feb-07-17	Initiated	Needham	Buy	$7
Mar-11-16	Reiterated	Maxim Group	Buy	$5 → $10
Jul-09-15	Downgrade	Piper Jaffray	Overweight → Neutral
Jan-23-15	Reiterated	Maxim Group	Buy	$7 → $9
Apr-28-14	Reiterated	Maxim Group	Buy	$10 → $7
Dec-19-13	Reiterated	Maxim Group	Buy	$6 → $10
Oct-05-12	Reiterated	Maxim Group	Buy	$3 → $6
May-31-12	Initiated	Maxim Group	Buy	$3
Sep-13-10	Reiterated	WBB Securities	Strong Buy	$8 → $9
Jul-30-10	Upgrade	WBB Securities	Buy → Strong Buy	$8
Apr-12-10	Initiated	Brean Murray	Buy	$8
Nov-11-08	Reiterated	Leerink Swann	Outperform	$8 → $4
Sep-17-08	Initiated	Leerink Swann	Outperform	$8
Aug-01-08	Initiated	Canaccord Adams	Buy	$6
Jun-19-08	Initiated	Lazard Capital	Buy	$7

Show Previous Ratings

Today 04:30PM	Athersys Licenses its Animal Health Assets to Ardent Animal Health (Business Wire)
Oct-02-23 05:04PM	Athersys Director Jane Wasman Appointed Board Chair (Business Wire)
Sep-06-23 02:45PM	Grant Awarded to Newcastle University to Research Athersys MultiStem® in Machine Perfusion Prior to Kidney Transplantation (Business Wire) -7.23%
Aug-25-23 11:36AM	Is Athersys Inc (ATHX) Significantly Overvalued? (GuruFocus.com)
Aug-17-23 09:30PM	Athersys, Inc. Announces Pricing of $3.5 Million Public Offering (Business Wire) -7.43%
05:01PM	Loading…
Aug-16-23 05:01PM	Athersys Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-15-23 04:51PM	20 States With The Longest Life Expectancy In America (Insider Monkey) -7.22%
Aug-11-23 08:00AM	Athersys Appoints Neema Mayhugh, PhD to its Board of Directors (Business Wire)
Aug-10-23 12:42PM	Athersys executives foresee catalysts that could ease its financial journey (American City Business Journals) +5.66%
Jul-31-23 01:38PM	Athersys to Host Business Update Conference Call on August 9th (Business Wire)
Jun-01-23 04:40PM	Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys MultiStem® Following Hemorrhagic Trauma (Business Wire)
May-23-23 08:30AM	Athersys Restructures Debt with Supplier (Business Wire) +8.02%
May-18-23 09:58AM	Athersys Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire) +11.91%
May-08-23 09:49AM	Athersys to Participate in Three Upcoming Conferences (Business Wire)
May-01-23 08:30AM	Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference (Business Wire) -6.37%
02:23PM	Loading…
Apr-21-23 02:23PM	Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference (Business Wire)
Apr-19-23 04:01PM	Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement (Business Wire)
Apr-18-23 08:00AM	Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement (Business Wire) -11.33%
Apr-10-23 03:29PM	Athersys to Host Business Update Conference Call on April 20th (Business Wire)
Mar-31-23 06:26PM	Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-22-23 08:30AM	Athersys Announces Successful Type B Meeting with the FDA (Business Wire) +21.19%
Feb-28-23 08:15AM	Athersys Expands IP Protection with First New Patent for SIFU® Technology (Business Wire)
Feb-14-23 03:40PM	Athersys is a 'very different company' from a year ago, CEO says (American City Business Journals) -16.10%
08:33AM	Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion (Business Wire)
Feb-02-23 08:30AM	Athersys to Host Business Update Conference Call on February 14th (Business Wire) +7.38%
Jan-30-23 11:20AM	Athersys to Participate in International Stroke Conference and BioProcess International (Business Wire)
Jan-11-23 07:15PM	Athersys shares take a wild ride while executives meet with investors (American City Business Journals) -17.65%
12:11PM	Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January (Business Wire)
Jan-10-23 11:59AM	Athersys shares rise as company managers meet with investors (American City Business Journals) +24.77%
Jan-09-23 08:30AM	Athersys Provides MultiStem Clinical Update (Business Wire) +13.54%
03:25PM	Loading…
Jan-06-23 03:25PM	Athersys appoints biotech veteran to board of directors (American City Business Journals) +13.60%
Jan-05-23 04:33PM	Athersys Appoints Joseph Nolan to Its Board of Directors (Business Wire)
Dec-28-22 09:59AM	Athersys, Inc. (NASDAQ:ATHX) Q3 2022 Earnings Call Transcript (Insider Monkey)
Nov-15-22 03:44PM	Athersys talking to 'new potential partners' for its stem cell technology (American City Business Journals) -16.15%
08:00AM	Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-11-22 08:30AM	Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.s Biotech Conference (Business Wire) +14.46%
Nov-10-22 03:12PM	Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering (Business Wire)
08:55AM	Athersys Reschedules Third Quarter Conference Call to November 15 (Business Wire)
Nov-09-22 11:58AM	Athersys may 'need to cease operations' if debt restructuring fails (American City Business Journals) -56.45%
08:59AM	Athersys, Inc. Announces Pricing of $5.5 Million Public Offering (Business Wire)
Nov-07-22 06:30PM	Athersys is planning a stock sale to raise operating cash (American City Business Journals) -8.87%
04:19PM	Athersys, Inc. Announces Proposed Public Offering (Business Wire)
Oct-25-22 08:30AM	Athersys to Host Third Quarter Financial Results Call (Business Wire)
Oct-04-22 09:25AM	Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October (Business Wire) -13.70%
Sep-30-22 12:33PM	Athersys to Host Business Update Conference Call on October 6th (Business Wire) +13.50%
Sep-23-22 02:34PM	Athersys could raise an additional $12.8M from unnamed institutional investor (American City Business Journals) +39.32%
09:19AM	Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering (Business Wire)
Sep-19-22 07:00AM	The Three Best Anti-Aging Stocks to Buy in September (InvestorPlace) -17.44%
Aug-29-22 06:02PM	Athersys shares lose 4.6% on first trading day after reverse stock split (American City Business Journals)
Aug-25-22 06:43PM	Athersys plans reverse stock split by Monday's market opening (American City Business Journals)
04:30PM	Athersys Announces 1-for-25 Reverse Stock Split (Business Wire)
Aug-17-22 04:30PM	Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering (Business Wire) -8.42%
Aug-15-22 12:16PM	Athersys plans to sell $12 million in securities to raise cash for operations (American City Business Journals)
08:30AM	Athersys, Inc. Announces $12 Million Registered Direct Offering (Business Wire)
Aug-14-22 08:13AM	News Flash: One Analyst Just Made An Incredible Upgrade To Their Athersys, Inc. (NASDAQ:ATHX) Forecasts (Simply Wall St.)
Aug-11-22 10:30PM	Athersys (ATHX) Q2 2022 Earnings Call Transcript (Motley Fool)
07:51PM	Athersys needs to raise capital to survive, CEO says (American City Business Journals)
04:17PM	Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-08-22 11:15AM	Radiation Countermeasure Study Data For U.S. Defense Department Gets First Readout (Benzinga) +11.15%
09:39AM	Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications (Business Wire)
Aug-04-22 12:03PM	Athersys hires turnaround consultant as interim CFO (American City Business Journals)
08:00AM	Athersys Appoints Kasey Rosado as Interim Chief Financial Officer (Business Wire)
Aug-02-22 03:34PM	Athersys shareholders vote to approve reverse stock split (American City Business Journals)
Jul-26-22 10:00AM	Athersys to Host Second Quarter Financial Results Call (Business Wire) -8.14%
Jul-08-22 12:14PM	Athersys loses $100M stock purchase agreement with Aspire Capital (American City Business Journals)
07:30AM	Athersys and Aspire Capital Fund Terminate Relationship (Business Wire)
Jul-05-22 08:30AM	Thinking about buying stock in Cowen, OneConnect Financial Tech, Faraday Future Intelligent Electric, RA Medical Systems, or Athersys? (PR Newswire)
Jun-28-22 02:07PM	Hunter Technology Provides Bi-Weekly Default Status Report (Newsfile)
Jun-21-22 06:00AM	Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures (Business Wire) -6.27%
Jun-17-22 02:55PM	Athersys shares rebound somewhat since falling by two-thirds on clinical trial results (American City Business Journals) -12.87%
Jun-15-22 08:43AM	Athersys (NASDAQ:ATHX) adds US$19m to market cap in the past 7 days, though investors from three years ago are still down 79% (Simply Wall St.)
Jun-09-22 01:02PM	Athersys to ask shareholders to approve reverse stock split (American City Business Journals)
07:00AM	Athersys Postpones Annual Meeting of Stockholders (Business Wire)
Jun-08-22 02:45PM	Athersys Hosting KOL Panel Event to Discuss TREASURE Data (Business Wire) +28.42%
Jun-02-22 06:35PM	Athersys to cut up to 70% of its workers in effort to survive (American City Business Journals) +7.71%
04:05PM	Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs (Business Wire)
May-23-22 03:32PM	Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal (Zacks) -17.88%
May-20-22 10:21AM	Athersys-Partnered Japanese Ischemic Stroke Study Disappoints, Shares Plunge (Benzinga) -65.54%
03:26AM	Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study (Business Wire)
May-13-22 08:00AM	Athersys to Participate in the H.C. Wainwright Global Investment Conference (Business Wire) +5.33%
May-11-22 06:35AM	7 Biotech Stocks With Key Catalysts for May (InvestorPlace) -11.85%
May-06-22 08:00AM	Athersys Reports First Quarter 2022 Results (Business Wire) +12.17%
May-02-22 09:00AM	Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference (Business Wire) +16.40%
Apr-29-22 09:00AM	Athersys to Announce First Quarter Financial Results on May 6 (Business Wire) +5.24%
Apr-04-22 03:40PM	Athersys closing in on commercialization of its stem cell therapy (American City Business Journals)
10:22AM	Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA (Zacks)
06:00AM	Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan (Business Wire)
Apr-01-22 04:46PM	Athersys to Participate in Two Upcoming Investor Conferences (Business Wire)
12:17PM	Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies (Zacks)
08:40AM	Athersys execs working to address Nasdaq deficiency letter, new CEO says (American City Business Journals)
Mar-28-22 12:19PM	Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM (Zacks)
Mar-16-22 06:23PM	Athersys may be close to commercializing stem cell therapy, new CEO of Cleveland company says (American City Business Journals)
12:00PM	Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why (Zacks)
Mar-15-22 04:05PM	Athersys Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights (Business Wire)
11:35AM	AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal (Zacks)
Mar-10-22 11:50AM	Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA (Zacks)
Mar-08-22 10:56AM	Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review (Zacks)
Feb-23-22 09:40AM	Is Athersys, Inc. (ATHX) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.07%
Feb-18-22 03:21PM	Athersys CEO Daniel Camardo's stock option grant worth $8.6 million (American City Business Journals)
Feb-17-22 04:30PM	Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Camardo Daniel A.	CEO	Nov 22	Buy	0.55	100,000	54,960	368,804	Nov 22 03:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHX | Athersys Inc

Upgrade your FINVIZ experience